Kenneth M. Boucher

Kenneth M. Boucher, PhD

Languages spoken: English

Academic Information

Departments Primary - Internal Medicine , Adjunct - Family & Preventive Medicine , Adjunct - Population Health Sciences

Divisions: Epidemiology , Public Health

Lab

Research Interests

  • Biostatistics
  • Mathematical Modeling
  • Topology
  • Statistical Consulting
  • Grant Writing

Dr. Kenneth Boucher is Co-Director of the Cancer Biostatistics Shared Resource at Huntsman Cancer Institute at the University of Utah. He is a Research Associate Professor in the Department of Internal Medicine and Adjunct Associate Professor in the Department of Family and Preventive Medicine and the Department of Population Health Sciences. He has been at the University of Utah since 1990 and at the Huntsman Cancer Institute since 1996. He is a member of the Cancer Control and Population Sciences Program at HCI.

Dr. Boucher has numerous research interests in the fields of cancer biostatistics and mathematical modeling. These interests include clinical trials, analysis high throughput genomics, carcinogenesis modeling, and cancer epidemiology.

Cancer Biostatistics Shared Resource webpage: https://uofuhealth.utah.edu/huntsman/shared-resources/cancer-biostatistics/

Education History

Doctoral Training University of Michigan
 PhD
Graduate Training University of Notre Dame
 MS
Undergraduate Washington University
 BS

Selected Publications

Journal Article

  1. Deacon DC, Stubben C, Marcacci E, Stone CJ, Birdsall M, Florell SR, Boucher K, Grossman D, Judson-Torres RL (2024). Classification of Cutaneous Melanoma and Melanocytic Nevi with MicroRNA Ratios Is Preserved in the Acral Melanoma Subtype. J Invest Dermatol. (Read full article)
  2. Wee Y, Wang J, Wilson EC, Rich CP, Rogers A, Tong Z, DeGroot E, Gopal YNV, Davies MA, Ekiz HA, Tay JKH, Stubben C, Boucher KM, Oviedo JM, Fairfax KC, Williams MA, Holmen SL, Wolff RK, Grossmann AH (2024). Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy. Nat Commun, 15(1), 6613. (Read full article)
  3. Vaklavas C, Matsen CB, Chu Z, Boucher KM, Scherer SD, Pathi S, Beck A, Brownson KE, Buys SS, Chittoria N, DAstous E, Gulbahce HE, Henry NL, Kimani S, Porretta J, Rosenthal R, Ward J, Wei M, Welm BE, Welm AL (2024). TOWARDS Study: Patient-Derived Xenograft Engraftment Predicts Poor Survival in Patients With Newly Diagnosed Triple-Negative Breast Cancer. JCO Precis Oncol, 8, e2300724. (Read full article)
  4. Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta S (2024). Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO Precis Oncol, 8, e2300697. (Read full article)
  5. Fastner S, Rahman H, Gutierrez J, Shen N, Florell SR, Florell A, Stubben CJ, Boucher KM, Deacon DC, Judson-Torres RL, Grossman D (2024). MicroRNA Signatures Associated with Basal Cell Carcinoma Subtypes. JID Innov, 4(4), 100286. (Read full article)
  6. McKean WB, Yang J, Boucher K, Shrieve DC, Suneja G, Salzman K, Jensen R, Colman H, Cohen AL (2024). D-TERMINED, a phase 1 trial in newly diagnosed high-grade glioma with temozolomide, radiation, and minocycline followed by adjuvant minocycline/temozolomide. Neurooncol Adv, 6(1), vdae063. (Read full article)
  7. Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan BL (2024). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). Oncologist, 29(5), 450-e725. (Read full article)
  8. Wu YP, Tercyak KP, Wankier AP, Brunsgaard EK, Parsons BG, Devine KA, Stump TK, Boucher KM, Hay JL (2023). Moderating influences on parents' fatalistic beliefs about cancer and their association with sun safety behaviors among children of melanoma survivors: Implications for treatment. J Health Psychol, 29(5), 13591053231209167. (Read full article)
  9. Winkler N, Buxton J, Freer P, Raps E, Barraza G, Boucher K, Riegert J, Factor R (2022). Comparison of Diagnostic Sensitivity and Procedure-Related Pain of Concurrent Ultrasound-guided Fine-needle Aspiration and Core-needle Biopsy of Axillary Lymph Nodes in Patients with Suspected or Known Breast Cancer. J Breast Imaging, 5(4), 436-444. (Read full article)
  10. Wu YP, Stump TK, Hay JL, Aspinwall LG, Boucher KM, Deboeck PR, Grossman D, Mooney K, Leachman SA, Smith KR, Wankier AP, Brady HL, Hancock SE, Parsons BG, Tercyak KP (2023). The family lifestyles, actions and risk education (FLARE) study: Protocol for a randomized controlled trial of a sun protection intervention for children of melanoma survivors. Contemp Clin Trials, 131, 107276. (Read full article)
  11. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah H (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of realworld outcomes. Haematologica, 108(11), 3025-3032. (Read full article)
  12. Boylan K, Kanth P, Delker D, Hazel MW, Boucher KM, Affolter K, Clayton F, Evason K, Jedrzkiewicz J, Pletneva M, Samowitz W, Swanson E, Bronner MP (2023). Three Pathologic Criteria for Reproducible Diagnosis of Colonic Sessile Serrated Lesion Versus Hyperplastic Polyp. Hum Pathol, 137, 25-35. (Read full article)
  13. Brunsgaard EK, Bowles TL, Asare EA, Grossmann K, Boucher KM, Grossmann A, Jackson JA, Wada DA, Rathore R, Budde G, Grandemange A, Hyngstrom JR (2023). Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma Res, 33(3), 184-191. (Read full article)
  14. Kunz JN, Huang YJ, Casper AC, Suneja G, Burt LM, Jhingran A, Joyner MM, Harkenrider MM, Small W Jr, Grant JD, Kidd EA, Boucher K, Gaffney DK (2023). Dosimetric Evaluation of OARs from SAVE Protocol. Int J Radiat Oncol Biol Phys. (Read full article)
  15. Himbert C, Ose J, Gigic B, Viskochil R, Santuci K, Lin T, Ashworth A, Cohan JN, Scaife CL, Jedrzkiewicz J, Damerell V, Atkins KM, Gong J, Mutch MG, Bernadt C, Felder S, Sanchez J, Cohen SA, Krane MK, Hinkle N, Wood E, Peoples AR, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Shibata D, Boucher K, Round JL, Ulrich AB, Schneider M, Huang LC, Hardikar S, Ulrich CM (2023). Associations of combined physical activity and body mass index groups with colorectal cancer survival outcomes. BMC Cancer, 23(1), 300. (Read full article)
  16. Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan BL (2023). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. Oncologist, 28(8), 737-e693. (Read full article)
  17. Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal R, Porretta J, Brownson KE, Matsen CB, Vaklavas C, Ward JH, Wei M, Buys SS, Chittoria N, Yakish ED, Archibald ZG, Burrell LD, Butterfield RI, Yap JT (2023). Prospective Pilot Study of (18)F-Fluoroestradiol PET/CT in Patients With Invasive Lobular Carcinomas. AJR Am J Roentgenol, 221(2), 228-239. (Read full article)
  18. Firpo MA, Boucher KM, Bleicher J, Khanderao GD, Rosati A, Poruk KE, Kamal S, Marzullo L, De Marco M, Falco A, Genovese A, Adler JM, De Laurenzi V, Adler DG, Affolter KE, Garrido-Laguna I, Scaife CL, Turco MC, Mulvihill SJ (2023). Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. JCO Clin Cancer Inform, 7, e2200160. (Read full article)
  19. Wen-Ying Wong E, Pandeya S, Crandall H, Smart T, Dixon M, Boucher KM, Florell SR, Grossman D, Sanchez B (2023). Electrical Impedance Dermography Differentiates Squamous Cell Carcinoma In Situ from Inflamed Seborrheic Keratoses. JID Innov, 3(3), 100194. (Read full article)
  20. Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta S (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC Res Notes, 16(1), 16. (Read full article)
  21. Sahu KK, Johnson ED, Butler K, Li H, Boucher KM, Gupta S (2022). Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool. Geriatrics (Basel), 7(6). (Read full article)
  22. Himbert C, Stephens WZ, Gigic B, Hardikar S, Holowatyj AN, Lin T, Ose J, Swanson E, Ashworth A, Warby CA, Peoples AR, Nix D, Jedrzkiewicz J, Bronner M, Pickron B, Scaife C, Cohan JN, Schrotz-King P, Habermann N, Boehm J, Hullar M, Figueiredo JC, Toriola AT, Siegel EM, Li CI, Ulrich AB, Shibata D, Boucher K, Huang LC, Schneider M, Round JL, Ulrich CM (2022). Differences in the gut microbiome by physical activity and BMI among colorectal cancer patients. Am J Cancer Res, 12(10), 4789-4801. (Read full article)
  23. Clark KA, Paquette A, Tao K, Bell R, Boyle JL, Rosenthal J, Snow AK, Stark AW, Thompson BA, Unger J, Gertz J, Varley KE, Boucher KM, Goldgar DE, Foulkes WD, Thomas A, Tavtigian SV (2021). Comprehensive evaluation and efficient classification of BRCA1 RING domain missense substitutions. Am J Hum Genet, 109(6), 1153-1174. (Read full article)
  24. Rogers CR, Perdue DG, Boucher K, Korous KM, Brooks E, Petersen E, Inadomi JM, Tuuhetaufa F, Levant RF, Paskett ED (2022). Masculinity Barriers to Ever Completing Colorectal Cancer Screening among American Indian/Alaska Native, Black, and White Men (Ages 45-75). Int J Environ Res Public Health, 19(5). (Read full article)
  25. Okwundu N, Rahman H, Liu T, Florell SR, Boucher KM, Grossman D (2021). A randomized double-blind placebo-controlled trial of oral aspirin for protection of melanocytic nevi against UV-induced DNA damage. Cancer Prev Res (Phila), 15, 129-138. (Read full article)
  26. Stephens DM, Boucher K, Kander E, Parikh SA, Parry EM, Shadman M, Pagel JM, Cooperrider J, Rhodes J, Mato A, Winter A, Hill B, Gaballa S, Danilov A, Phillips T, Brander DM, Smith SM, Davids M, Rogers K, Glenn MJ, Byrd JC (2021). Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. Haematologica, 106(11), 2845-2852. (Read full article)
  27. Maughan BL, Kessel A, McFarland TR, Sayegh N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Sirohi D, Kohli M, Swami U, Boucher K, Haaland B, Agarwal N (2021). Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 26, 1006-e2129. (Read full article)
  28. Binneboese A, Covington MF, Horn KP, Archibald ZG, Boucher KM, Morton KA, Hoffman JM (2021). Correlation between FDG-PET uptake and survival in patients with primary brain tumors. Am J Nucl Med Mol Imaging, 11(3), 196-206. (Read full article)
  29. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY (2021). Correction: Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res, 27(11), 3265. (Read full article)
  30. Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510. (Read full article)
  31. Flint ND, Bishop MD, Smart TC, Strunck JL, Boucher KM, Grossman D, Secrest AM (2020). Low accuracy of self-reported family history of melanoma in high-risk patients. Fam Cancer, 20(1), 41-48. (Read full article)
  32. Rahman H, Kumar D, Liu T, Okwundu N, Lum D, Florell SR, Burd CE, Boucher KM, VanBrocklin MW, Grossman D (2020). Aspirin Protects Melanocytes and Keratinocytes against UVB-Induced DNA Damage In Vivo. J Invest Dermatol, 141(1), 132-141.e3. (Read full article)
  33. Holowatyj AN, Haffa M, Lin T, Scherer D, Gigic B, Ose J, Warby CA, Himbert C, Abbenhardt-Martin C, Achaintre D, Boehm J, Boucher KM, Gicquiau A, Gsur A, Habermann N, Herpel E, Kauczor HU, Keski-Rahkonen P, Kloor M, von Knebel-Doeberitz M, Kok DE, Nattenmller J, Schirmacher P, Schneider M, Schrotz-King P, Simon T, Ueland PM, Viskochil R, Weijenberg MP, Scalbert A, Ulrich A, Bowers LW, Hursting SD, Ulrich CM (2020). Multi-omics Analysis Reveals Adipose-tumor Crosstalk in Patients with Colorectal Cancer. Cancer Prev Res (Phila), 13(10), 817-828. (Read full article)
  34. Tavtigian SV, Harrison SM, Boucher KM, Biesecker LG (2020). Fitting a naturally scaled point system to the ACMG/AMP variant classification guidelines. Hum Mutat, 41(10), 1734-1737. (Read full article)
  35. Rogers CR, Matthews P, Xu L, Boucher K, Riley C, Huntington M, Le Duc N, Okuyemi KS, Foster MJ (2020). Interventions for increasing colorectal cancer screening uptake among African-American men: A systematic review and meta-analysis. PLoS One, 15(9), e0238354. (Read full article)
  36. Cowman SJ, Fuja DG, Liu XD, Tidwell RSS, Kandula N, Sirohi D, Agarwal AM, Emerson LL, Tripp SR, Mohlman JS, Stonhill M, Garcia G, Conley CJ, Olalde AA, Sargis T, Ramirez-Torres A, Karam JA, Wood CG, Sircar K, Tamboli P, Boucher K, Maughan B, Spike BT, Ho TH, Agarwal N, Jonasch E, Koh MY (2020). Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clin Cancer Res, 26(18), 4970-4982. (Read full article)
  37. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5. (Read full article)
  38. Cohen AL, Anker CJ, Johnson B, Burt LM, Shrieve DC, Salzman K, Jensen R, Boucher K, Colman H (2020). Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. J Neurooncol, 148(3), 577-585. (Read full article)
  39. Li C, Liu T, Tavtigian SV, Boucher K, Kohlmann W, Cannon-Albright L, Grossman D (2019). Targeted germline sequencing of patients with three or more primary melanomas reveals high rate of pathogenic variants. Melanoma Res, 30(3), 247-251. (Read full article)
  40. Agarwal N, Nussenzveig R, Hahn AW, Hoffman JM, Morton K, Gupta S, Batten J, Thorley J, Hawks J, Santos VS, Nachaegari G, Wang X, Boucher K, Haaland B, Maughan BL (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res, 26(9), 2104-2110. (Read full article)
  41. Drost M, Tiersma Y, Glubb D, Kathe S, van Hees S, Callja F, Zonneveld JBM, Boucher KM, Ramlal RPE, Thompson BA, Rasmussen LJ, Greenblatt MS, Lee A, Spurdle AB, Tavtigian SV, de Wind N (2020). Two integrated and highly predictive functional analysis-based procedures for the classification of MSH6 variants in Lynch syndrome. Genet Med, 22(5), 847-856. (Read full article)
  42. Strunck JL, Smart TC, Boucher KM, Secrest AM, Grossman D (2020). Improved melanoma outcomes and survival in patients monitored by total body photography: A natural experiment. J Dermatol, 47(4), 342-347. (Read full article)
  43. Varedi A, Rahman H, Kumar D, Catrow JL, Cox JE, Liu T, Florell SR, Boucher KM, Okwundu N, Burnett WJ, VanBrocklin MW, Grossman D (2020). ASA Suppresses PGE2 in Plasma and Melanocytic Nevi of Human Subjects at Increased Risk for Melanoma. Pharmaceuticals (Basel), 13(1). (Read full article)
  44. Wu YP, Boucher K, Hu N, Hay J, Kohlmann W, Aspinwall LG, Bowen DJ, Parsons BG, Nagelhout ES, Grossman D, Mooney K, Leachman SA, Tercyak KP (2019). A pilot study of a telehealth family-focused melanoma preventive intervention for children with a family history of melanoma. Psychooncology, 29(1), 148-155. (Read full article)
  45. Kohli DR, Smith KR, Wong J, Yu Z, Boucher K, Faigel DO, Pannala R, Burt RW, Curtin K, Samadder NJ (2019). Familial pancreatic cancer risk: a population-based study in Utah. J Gastroenterol, 54(12), 1106-1112. (Read full article)
  46. Kanth P, Boylan KE, Bronner MP, Boucher KM, Hazel MW, Yao R, Pop S, Bernard PS, Delker DA (2019). Molecular Biomarkers of Sessile Serrated Adenoma/Polyps. Clin Transl Gastroenterol, 10(12), e00104. (Read full article)
  47. Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL (2019). AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis. Mol Cancer Res, 17(9), 1787-1800. (Read full article)
  48. Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421. (Read full article)
  49. Weldon Gilcrease G, Stenehjem DD, Wade ML, Weis J, McGregor K, Whisenant J, Boucher KM, Thorne K, Orgain N, Garrido-Laguna I, Sharma S (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer. Invest New Drugs, 37(3), 482-489. (Read full article)
  50. Cohen AL, Neumayer L, Boucher K, Factor RE, Shrestha G, Wade M, Lamb JG, Arbogast K, Piccolo SR, Riegert J, Schabel M, Bild AH, Werner TL (2017). Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker. JCO Precis Oncol, 1. (Read full article)
  51. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, Hankins P, Grupp SA, Bunin N (2009). A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol, 147(5), 691-9. (Read full article)
  52. Yakovlev AY, Tsodikov AD, Boucher K, Kerber R (1999). The shape of the hazard function in breast carcinoma: curability of the disease revisited. Cancer, 85(8), 1789-98. (Read full article)
  53. Yakovlev A, Boucher K, DiSario J (1999). Modeling insight into spontaneous regression of tumors. Math Biosci, 155(1), 45-60. (Read full article)

Letter

  1. Varedi A, Bishop MD, Boucher KM, Kim CC, Grossman D (2019). Powering a prospective melanoma chemoprevention trial in high-risk cohorts. [Letter to the editor]. Int J Dermatol, 58(11), e232-e234. (Read full article)

Patent

  1. Szabo A, Boucher K, Jones D, L. Klebanov Tsodikov A, Yakovlev A (2002). Methods for identifying large subsets of differentially expressed genes based on multivariate microarray data.
  2. Szabo A, . Yakovlev A, Boucher K, Tsodikov A, Jones D, Klebanov L (2001). Methods for identifying differentially expressed genes by multivariate analysis of microarray data.